Correlation Between Karyopharm Therapeutics and Neurocrine Biosciences

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Neurocrine Biosciences, you can compare the effects of market volatilities on Karyopharm Therapeutics and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Neurocrine Biosciences.

Diversification Opportunities for Karyopharm Therapeutics and Neurocrine Biosciences

-0.5

Correlation Coefficient

Karyopharm Therapeutics  Neurocrine Biosciences

Very good diversification

The 3 months correlation between Karyopharm and Neurocrine is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Neurocrine Biosciences

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Neurocrine Biosciences. In addition to that, Karyopharm Therapeutics is 1.82 times more volatile than Neurocrine Biosciences. It trades about -0.04 of its total potential returns per unit of risk. Neurocrine Biosciences is currently generating about 0.0 per unit of volatility. If you would invest  14,011  in Neurocrine Biosciences on September 27, 2024 and sell it today you would lose (358.00) from holding Neurocrine Biosciences or give up 2.56% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Neurocrine Biosciences

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Neurocrine Biosciences

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady forward indicators, Neurocrine Biosciences showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Karyopharm Therapeutics and Neurocrine Biosciences

The main advantage of trading using opposite Karyopharm Therapeutics and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.

The idea behind Karyopharm Therapeutics and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.